GlassScriptPhysician profile
Charlene Grace
NPI 1174839526
$3,548.96
in general payments reported to CMS, 2019-2025
35 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $271 · 2023: $608 · 2024: $1,352 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,278.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,026.95 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $299.57 | 2023-2025 | |
| Lilly USA, LLC | $273.15 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $180.83 | 2024-2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $171.26 | 2022-2025 | Gardasil 9, Verquvo, Capvaxive |
| Renalytix Ai, INC. | $161.70 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Bayer Healthcare Pharmaceuticals INC. | $160.60 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $118.71 | 2024 | |
| Amgen INC. | $115.10 | 2022-2025 | Repatha, Otezla, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.75 | 2025 | Jardiance |
| Medicomp INC | $80.29 | 2022-2025 | Telepatch Cardiac Monitor |
| Glaxosmithkline, LLC. | $76.60 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $72.80 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $68.38 | 2025 | Recorlev |
| Recordati_rare_diseases_inc. | $65.74 | 2025 | Isturisa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $51.80 | 2023 | Ibsrela |
| Verity Pharmaceuticals INC. | $45.58 | 2024 | Tlando |
| Hologic Sales and Service, LLC | $44.49 | 2025 | Aptima |
| Mannkind Corporation | $39.52 | 2025 | |
| Intra-Sana Laboratories | $37.60 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Janssen Pharmaceuticals, INC | $36.33 | 2025 | Spravato |
| Shield Therapeutics INC | $35.50 | 2023 | Accrufer |
| Alkermes, INC. | $33.75 | 2022-2023 | Vivitrol |
| Antares Pharma, INC. | $30.45 | 2025 | Xyosted |
| Tolmar, INC. | $27.33 | 2024 | |
| Medtronic, INC. | $26.27 | 2024 | Ligasure |
| Amneal Pharmaceuticals LLC | $24.73 | 2024 | Unithroid |
| Eisai INC. | $23.72 | 2025 | |
| Astellas Pharma US INC | $23.20 | 2025 | Veozah |
| Philips North America LLC | $19.27 | 2024 | (Ck7) Extended Holter |
| Pfizer INC. | $18.78 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $15.52 | 2024 | Rexulti |
| Corium, LLC | $14.60 | 2023 | Azstarys |
| Inspire Medical Systems, INC. | $14.26 | 2025 | Inspire |
| Spinal Elements, INC. | $12.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlene Grace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.